n'a finalement pas été retenue puisque l'HT adjuvante ne concerne que les cancers du sein et non l'ensemble des 3 cancers étudiés ,
3 ng/mL était significativement associé à un risque de survenue d'une toxicité environ 4 fois plus important lorsque la C 0 est supérieure à 26, pp.95-143 ,
Analyse de Cox univariée Les variables « C 0 d'EVR binarisée » selon le seuil de 11 ,
9 ng/mL était significativement associé à une progression tumorale avec un risque 3,2 fois plus important lorsque la C 0 est inférieure à 11, pp.95-128 ,
TC était associé à un risque de progression tumorale 1,7 fois plus important ,
??l??ments de l???interpr??tation et du dialogue clinico-biologique pour quelques param??tres usuels de pharmacologie-toxicologie, Th??rapie, vol.71, issue.4, pp.405-434, 2016. ,
DOI : 10.1016/j.therap.2016.01.007
The Role of Therapeutic Monitoring of Everolimus in Solid Organ Transplantation, Therapeutic Drug Monitoring, vol.27, issue.5, pp.666-676, 2005. ,
DOI : 10.1097/01.ftd.0000175911.70172.2e
Therapeutic Drug Monitoring for Everolimus in Heart Transplant Recipients Based on Exposure-Effect Modeling, American Journal of Transplantation, vol.3, issue.5, pp.2126-2131, 2004. ,
DOI : 10.1056/NEJMoa021744
Everolimus Therapeutic Concentration Range Defined from a Prospective Trial with Reduced-Exposure Cyclosporine in De Novo Kidney Transplantation, Therapeutic Drug Monitoring, vol.26, issue.5 ,
DOI : 10.1097/00007691-200410000-00007
Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range, Transplantation, vol.73, issue.6, pp.920-925, 2002. ,
DOI : 10.1097/00007890-200203270-00016
Therapeutic Drug Monitoring of Everolimus, Therapeutic Drug Monitoring, vol.38, issue.2, pp.143-169, 2016. ,
DOI : 10.1097/FTD.0000000000000260
Relationship between everolimus exposure and safety and efficacy: Meta-analysis of clinical trials in oncology, European Journal of Cancer, vol.50, issue.3, pp.486-495, 1990. ,
DOI : 10.1016/j.ejca.2013.11.022
RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs, Cell, vol.78, issue.1, pp.35-43, 1994. ,
DOI : 10.1016/0092-8674(94)90570-3
A mammalian protein targeted by G1-arresting rapamycin???receptor complex, Nature, vol.369, issue.6483, pp.756-758, 1994. ,
DOI : 10.1038/369756a0
Everolimus in Postmenopausal Hormone-Receptor???Positive Advanced Breast Cancer, New England Journal of Medicine, vol.366, issue.6, pp.520-529, 2012. ,
DOI : 10.1056/NEJMoa1109653
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, The Lancet, vol.372, issue.9637, pp.449-456, 2008. ,
DOI : 10.1016/S0140-6736(08)61039-9
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study, The Lancet, vol.378, issue.9808, pp.2005-2012, 2011. ,
DOI : 10.1016/S0140-6736(11)61742-X
Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis, Advances in Therapy, vol.182, issue.3, pp.870-884, 2013. ,
DOI : 10.1007/s12325-013-0060-1
Everolimus in Combination with Exemestane: A Review of its Use in the Treatment of Patients with Postmenopausal Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer, Drugs, vol.28, issue.30, pp.475-485, 2013. ,
DOI : 10.1007/s40265-013-0034-2
Real-world study of everolimus in advanced progressive neuroendocrine tumors, The Oncologist, vol.20, issue.570, 2015. ,
Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer, Annals of Oncology, vol.25, issue.4, pp.763-773, 2014. ,
DOI : 10.1093/annonc/mdu021
Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: Results of a pooled analysis of non-interventional studies, European Journal of Cancer, vol.51, issue.16 ,
DOI : 10.1016/j.ejca.2015.07.030
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2, Annals of Oncology, vol.25, issue.4, pp.808-815, 2014. ,
DOI : 10.1093/annonc/mdu009
Pharmacogenetics or the promise of a personalized medicine: variability in drug metabolism and transport], Ann. Biol. Clin. (Paris), vol.62, pp.499-511, 2004. ,
Pharmacog??n??tique des m??dicaments anticanc??reux, Pathologie Biologie, vol.53, issue.2, pp.116-124, 2005. ,
DOI : 10.1016/j.patbio.2004.05.001
CYP3A5 Genotype Does Not Influence Everolimus In Vitro Metabolism and Clinical Pharmacokinetics in Renal Transplant Recipients, Transplantation, vol.91, issue.6, pp.652-656, 2011. ,
DOI : 10.1097/TP.0b013e31820ae4ac
URL : https://hal.archives-ouvertes.fr/inserm-00542366
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs, The Pharmacogenomics Journal, vol.34, issue.4, pp.274-286, 2011. ,
DOI : 10.2217/pgs.09.42
polymorphism on calcineurin inhibitors??? dose requirements and trough blood levels in stable renal transplant patients, Pharmacogenomics, vol.12, issue.10, pp.1383-1396, 2011. ,
DOI : 10.2217/pgs.11.90
Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study, Pharmacogenetics and Genomics, vol.21, issue.12, pp.861-866, 2011. ,
DOI : 10.1097/FPC.0b013e32834c6edb
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression, Nature Genetics, vol.27, issue.4, pp.383-391, 2001. ,
DOI : 10.1038/86882
CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy*1, Clinical Pharmacology & Therapeutics, vol.75, issue.6, pp.529-538, 2004. ,
DOI : 10.1016/j.clpt.2004.02.005
The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients, Pharmacogenetics, vol.14, issue.3, pp.147-154, 2004. ,
DOI : 10.1097/00008571-200403000-00002
CYP3A5 Genotype has an Impact on the Metabolism of the HIV Protease Inhibitor Saquinavir, Clinical Pharmacology & Therapeutics, vol.784, issue.5, pp.708-712, 2007. ,
DOI : 10.1038/sj.clpt.6100117
Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD, Transplantation Proceedings, vol.33, issue.1-2, pp.514-515, 2001. ,
DOI : 10.1016/S0041-1345(00)02116-3
Phase 3 trial of everolimus for metastatic renal cell carcinoma, Cancer, vol.356, issue.suppl, pp.4256-4265, 2010. ,
DOI : 10.1002/cncr.25219
Population Pharmacokinetics of Everolimus in Cardiac Recipients, Therapeutic Drug Monitoring, vol.34, issue.6, pp.686-694, 2012. ,
DOI : 10.1097/FTD.0b013e318273c899
Population Pharmacokinetics and Pharmacogenetics of Everolimus in Renal Transplant Patients, Clinical Pharmacokinetics, vol.13, issue.3, pp.467-480, 2012. ,
DOI : 10.2165/11599710-000000000-00000
The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients, Clinical Transplantation, vol.11, issue.5, pp.590-597, 2014. ,
DOI : 10.1111/ctr.12350
Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation, CPT: Pharmacometrics Systems Pharmacology, vol.64, issue.2, p.100, 2014. ,
DOI : 10.1016/j.cmpb.2010.04.018
The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation, Clinical Transplantation, vol.8, issue.1, pp.146-150, 2011. ,
DOI : 10.1111/j.1399-0012.2009.01198.x
Practical, Individualized Dosing: 21st Century Therapeutics and the Clinical Pharmacometrician, The Journal of Clinical Pharmacology, vol.48, issue.7, pp.842-847, 2010. ,
DOI : 10.1177/0091270009356572
Focus on mTOR inhibitors and tacrolimus in renal transplantation: Pharmacokinetics, exposure???response relationships, and clinical outcomes, Transplant Immunology, vol.31, issue.1, pp.22-32, 2014. ,
DOI : 10.1016/j.trim.2014.05.002
Effect of Food on Everolimus Absorption: Quantification in Healthy Subjects and a Confirmatory Screening in Patients with Renal Transplants, Pharmacotherapy, vol.39, issue.2, pp.154-159, 2002. ,
DOI : 10.1023/A:1011940108365